Question: What biomarker strategy should we use for KRAS G12C NSCLC therapy selection?
Use a KRAS G12C-focused biomarker strategy that confirms mutation status, captures NSCLC clinical context, and links eligibility to targeted therapy evidence and clinical-trial options.
Research use only. Public/synthetic demo evidence only; not clinical advice.
| Source | Tier | Reliability | Summary |
|---|---|---|---|
| FDA label and regulatory evidence for KRAS G12C-mutated NSCLC | Regulatory label | 0.98 | Regulatory labels support KRAS G12C status as a therapy-selection biomarker in the appropriate NSCLC context. |
| Peer-reviewed KRAS G12C NSCLC translational literature | Peer-reviewed literature | 0.86 | Published evidence supports molecular testing, resistance review, and structured biomarker strategy design. |
| Clinical trial registry evidence | Clinical trial registry | 0.82 | Trial eligibility and stratification criteria can be inspected for biomarker and treatment-context requirements. |